Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agios Pharma (NASDAQ:AGIO) and PTC Therapeutics (NASDAQ:PTCT).
Agios Pharma (AGIO)
Oppenheimer analyst Leah R. Cann maintained a Hold rating on Agios Pharma today. The company’s shares opened today at $88.79.
Cann commented:
“2018 loss per share was $1.19, compared to our estimate of $1.53. There were two unanticipated milestone payments in the quarter, which resulted in the higher than expected collaboration revenue. These included a $12.4 million payment from the CStone agreement and a $15 million payment from Celgene for the MAA filing for Idhifa to the EMA. Royalty revenue of $1.6 million was lower than our estimated $2.0 million due to scaling of royalties on Idhifa. Idhifa sales of $17.0 million were in line with our estimate of $16.8 million, and 29.2% higher than Q1 2018. Operating expenses of $113.4 million were 9.0% higher than our estimated $104.0 million, due to higher than estimated SG&A and R&D.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 24.5% and a 55.5% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Agios Pharma is a Strong Buy with an average price target of $106.67.
See today’s analyst top recommended stocks >>
PTC Therapeutics (PTCT)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on PTC Therapeutics. The company’s shares opened today at $37.57.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 21.1% and a 65.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $46 average price target, representing a 22.4% upside. In a report issued on July 24, Citigroup also maintained a Buy rating on the stock with a $50 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
